CCN2 and idiopathic pulmonary fibrosis: Therapeutic inhibition of CCN2 through the monoclonal antibody FG-3019/pamrevlumab yielded promising results in preclinical models of organ fibrosis148,149,150 as well as promising results in a phase 2 study in IPF patients.151